OXGN


Stock Update (NASDAQ:OXGN): OXiGENE Inc Receives U.S. Orphan Drug Designation for CA4P to Treat Glioma

OXiGENE Inc (NASDAQ:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that the U.S.

Stock Update (NASDAQ:OXGN): OXiGENE Inc Announces Results of Phase 2 Study of CA4P in Recurrent Ovarian Cancer Published in Journal of Clinical Oncology

OXiGENE Inc (NASDAQ:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced the online publication …

Company Update (NASDAQ:OXGN): OXiGENE Inc’s CA4P Granted FDA Fast Track Designation For Cancer

OXiGENE Inc (NASDAQ:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced that the U.S.

Company Update (NASDAQ:OXGN): OXiGENE Inc Reports 2015 Financial Results

OXiGENE Inc (NASDAQ:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today reported financial results for 2015. For the …

Company Update (NASDAQ:OXGN): OXiGENE Inc Receives U.S. Orphan Drug Designation for CA4P to Treat Neuroendocrine Tumors

OXiGENE Inc (NASDAQ:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, announced that the U.S.

Company Update (NASDAQ:OXGN): OXiGENE Inc Reports Third Quarter 2015 Financial Results

OXiGENE Inc (NASDAQ:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today reported financial results for the quarter ended …

Stock Update (NASDAQ:OXGN): OXiGENE Inc Announces Positive Initial Data From Phase 1b Study of CA4P in Combination With Pazopanib in Patients With Advanced Recurrent Ovarian Cancer

OXiGENE Inc (NASDAQ:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, announced initial data from a Phase 1b/2 study …

Company Update (NASDAQ:OXGN): OXiGENE Inc Announces Initiation of Phase 1b/2 Clinical Trial of OXi4503 in Acute Myeloid Leukemia

OXiGENE Inc (NASDAQ:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced that it has initiated a phase …

Company Update (NASDAQ:OXGN): OXiGENE Inc Announces Interim Phase 2 Data For Lead Clinical Candidate CA4P In Neuroendocrine Tumors

OXiGENE Inc (NASDAQ:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced the presentation of interim phase 2 data for the company’s lead …

MLV Reiterates Buy on OXiGENE Inc Following 2Q:15 Results

In a research report released Tuesday, MLV analyst Thomas Yip reiterated a Buy rating on shares of OXiGENE Inc (NASDAQ:OXGN) with a price target …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts